JPJoel Pires

Joel Pires

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joel Pires has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The tyrosine phosphatase STEP is a developmental suppressor of synaptogenesis

    by Joel P. Pires, Diogo Tomé, Miranda Mele, Ana Caulino-Rocha, Elisa Corti, Ira Milosevic, Graça F. Baltazar, Ramiro D. Almeida

    Striatal-Enriched Protein Tyrosine Phosphatase (STEP) constrains synaptic potentiation by dephosphorylating postsynaptic substrates, but its presynaptic role has remained unclear. Here, we identify a previously unrecognized function of STEP in regulating axonal differentiation and synapse assembly. Genetic and pharmacological manipulation of STEP in vivo and in vitro show that STEP limits presynaptic maturation by restricting synaptic vesicle protein clustering along developing hippocampal axons. Using a reconstituted circuit-on-a-chip we show that loss of presynaptic STEP is sufficient to significantly increase the number of axodendritic synapses. Functional imaging further revealed that the increased synaptic puncta observed in STEP KO neurons actively undergo depolarization-evoked vesicle exocytosis, representing bona fide functional synapses. Multielectrode array recordings reveal that STEP deletion increases neuronal excitability, and network synchrony, hallmarks of enhanced presynaptic efficacy. Mechanistically, these effects reflect sustained phosphorylation of STEP promoting presynaptic assembly and release competence. Importantly, inhibiting STEP also rescues presynaptic differentiation defects in Fmr1 KO neurons, implicating aberrant STEP signaling in Fragile X–associated synaptic pathology. Thus, STEP serves as a phosphatase gatekeeper that restrains presynaptic differentiation and neurotransmission, and its inhibition may offer a therapeutic strategy to correct synaptic deficits in Fragile X Syndrome.


  • Open Access

    Functionalized Nanodiamonds for Targeted Neuronal Electromagnetic Signal Detection

    by Beatriz N. L. Costa, Filipe Camarneiro, Ana Marote, Catarina Barbosa, Carlos Vedor, Diogo Tomé, Filipa J. Costa, Marta S. Dias, Joana Correia, Joel Pires, et al.

    Intracellular sensing technologies necessitate a delicate balance of spatial resolution, sensitivity, biocompatibility, and stability. While existing methods partially fulfill these criteria, none offer a comprehensive solution. Nanodiamonds (NDs) harboring nitrogen-vacancy (NV) centers have emerged as promising candidates due to their sensing capabilities under biological conditions and their ability to meet all aforementioned requirements. This study focuses on expanding the application of NDs and NV center-based sensing to neuronal contexts by investigating their functionalization and subsequent effects on three distinct cell lines relevant to neurodegenerative disease research. Our study concentrates on positioning fluorescent NDs (FNDs) with NV center point defects onto neuronal cell surfaces. Achieving this through specific antibody attachment enhances the proximity of FND to neurites, facilitating the detection of local action potentials. Targeting voltage-dependent calcium channels (Cav2.2) with biotin-streptavidin-bound antibodies enables the precise positioning of FNDs. The functionalized FNDs (f-FNDs) show increased size and zeta potential, confirming the antibody presence without compromising cell viability. Two-color confocal imaging and co-localization algorithms are employed to further attest to the success of the functionalization. The f-FNDs are applied to cell cultures of three cell lines: SH-SY5Y, differentiated dopaminergic neurons, and hippocampal rat neurons; their biocompatibility and effects on synaptic activity are explored. Moreover, preliminary total internal reflection fluorescence - optically detected magnetic resonance (TIRF-ODMR) experiments across cellular sites demonstrate the magnetic field sensitivity of our sensor network. The successful establishment of this sensor network provides a platform for characterizing neuronal signaling in healthy models and conditions mimicking Parkinson's disease.


  • Open Access

    Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3

    by Joana Sofia Correia, Andreia Neves-Carvalho, Bárbara Mendes-Pinheiro, Joel Pires, Fábio Gabriel Teixeira, Rui Lima, Susana Monteiro, Nuno André Silva, Carina Soares-Cunha, Sofia Cravino Serra, et al.

    The low regeneration potential of the central nervous system (CNS) represents a challenge for the development of new therapeutic strategies for neurodegenerative diseases, including spinocerebellar ataxias. Spinocerebellar ataxia type 3 (SCA3)—or Machado–Joseph disease (MJD)—is the most common dominant ataxia, being mainly characterized by motor deficits; however, SCA3/MJD has a complex and heterogeneous pathophysiology, involving many CNS brain regions, contributing to the lack of effective therapies. Mesenchymal stem cells (MSCs) have been proposed as a potential therapeutic tool for CNS disorders. Beyond their differentiation potential, MSCs secrete a broad range of neuroregulatory factors that can promote relevant neuroprotective and immunomodulatory actions in different pathophysiological contexts. The objective of this work was to study the effects of (1) human MSC transplantation and (2) human MSC secretome (CM) administration on disease progression in vivo, using the CMVMJD135 mouse model of SCA3/MJD. Our results showed that a single CM administration was more beneficial than MSC transplantation—particularly in the cerebellum and basal ganglia—while no motor improvement was observed when these cell-based therapeutic approaches were applied in the spinal cord. However, the effects observed were mild and transient, suggesting that continuous or repeated administration would be needed, which should be further tested.


  • Dual role of histamine on microglia-induced neurodegeneration

    by S. Barata-Antunes, A.C. Cristóvão, J. Pires, S.M. Rocha, L. Bernardino


  • Open Access

    Histamine: a new immunomodulatory player in the neuron-glia crosstalk

    by Sandra M. Rocha, Joel Pires, Marta Esteves, Baltazar Graã§A, Liliana Bernardino

    Histamine is an amine acting as a major peripheral inflammatory mediator. In the brain, histamine was initially viewed as a neurotransmitter, but new evidences support its involvement in the modulation of innate immune responses. Recently, we showed that histamine modulates microglial migration and cytokine release. Its pleiotropic actions, ranging from neurotransmission to inflammation, highlight histamine as a key player in a vast array of brain physiologic activities and also in the pathogenesis of several neurodegenerative diseases. Herein, we emphasize the role of histamine as a modulator of brain immune reactions, either by acting on invading peripheral immune cells and/or on resident microglial cells. We also unveil the putative involvement of histamine in the microglial-neuronal communication. We first show that histamine modulates the release of inflammatory mediators, namely nitric oxide, by microglia cells. Consequently, the microglia secretome released upon histamine stimulation fosters dopaminergic neuronal death. These data may reveal important new pharmacological applications on the use histamine and antihistamines, particularly in the context of Parkinson’s disease.